Experimental tomato-soy juice shows anti-inflammatory effects in obese adults

Researchers at Ohio State University have found that a simple juice made from tomato and soy can measurably reduce inflammation in obese adults—a discovery that hints at how food itself might become a tool against the chronic, silent damage that excess weight inflicts on the body.

The inflammation that accompanies obesity is not like the sharp pain of a cut or the fever of an infection. It is a low-grade alarm system that stays partially switched on, year after year, quietly damaging blood vessels, metabolism, the liver, and fatty tissue. This persistent inflammatory state is the engine behind type 2 diabetes, heart disease, and other metabolic disorders. It can run for years without producing any symptom the person would notice. The challenge for medicine is finding ways to turn down that alarm.

The Ohio State team tested a functional beverage formulated with two bioactive compounds: lycopene, the red pigment in tomatoes, and isoflavones from soy—both substances with known antioxidant and anti-inflammatory properties. Twelve adults with obesity participated in a crossover trial, meaning each person consumed both the enriched juice and a control drink made only from tomato. The enriched version delivered 54 milligrams of lycopene and nearly 190 milligrams of isoflavones daily, amounts substantially higher than what a typical Western diet provides. Each participant drank two 180-milliliter cans per day for four weeks.

The results, published in Molecular Nutrition & Food Research, showed significant reductions in three pro-inflammatory cytokines—IL-5, IL-12p70, and GM-CSF—molecules directly involved in sustained inflammatory processes. A fourth marker, TNF-alpha, trended downward but did not reach statistical significance. Blood samples also showed markedly elevated levels of lycopene, confirming the compounds were being absorbed and circulated through the body. Jessica Cooperstone, the lead author and an associate professor of horticulture and crop sciences at Ohio State, framed the underlying question plainly: "Can we use food-based interventions to modulate inflammation?"

The researchers went further, analyzing the metabolome in urine—the chemical fingerprint left behind when the body processes and eliminates food compounds. They found increased levels of metabolites derived from soy isoflavones, particularly conjugated forms linked to the metabolism of genistein. This was not merely evidence that the soy had been consumed; it showed the body had transformed these compounds through measurable metabolic pathways. One finding stood out: the presence of intact ethylphenol conjugates in urine after soy consumption, a result rarely documented before. For the authors, this suggested the intervention had altered the metabolic profile in ways that extended beyond the inflammatory markers themselves.

The mechanism remains incompletely understood. Both lycopene and isoflavones have been associated with cardiovascular and metabolic benefits in prior research, and both may influence cellular inflammatory pathways like NF-κB, a central system in the production of inflammatory signals. Yet Cooperstone cautioned against attributing the effect to any single compound in isolation. The benefit likely emerges from the interaction of multiple plant molecules working together—a growing insight in nutrition science that foods may act through complex combinations of bioactive substances rather than through individual nutrients alone.

The study carries clear limitations. Twelve participants is a small sample, one that demands cautious interpretation. The results cannot be generalized to broader populations, and larger, longer trials are needed to determine whether the effect holds across different patient profiles and over extended periods. Still, the work provides experimental evidence that a relatively straightforward dietary intervention can produce measurable changes in inflammatory biomarkers within four weeks. It opens a door to a question that may define the next phase of metabolic medicine: not just what to avoid, but what to deliberately consume to quiet the body's chronic alarm.